BYD Presents Strong New Energy Vehicle Line-Up at IAA and Premieres the SEAL U in Europe
5.9.2023 19:18:00 CEST | Business Wire | Press Release
BYD, the world’s leading manufacturer of new energy vehicles (NEVs), unveils a full spectrum of electric passenger car innovation to European consumers at the Internationale Automobilausstellung (IAA) in Munich. BYD presents five all-electric cars equipped with pioneering EV technologies, together with a sixth new energy model, the DENZA D9, an exclusive European premiere of the premium BYD sub-brand, DENZA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905076263/en/
BYD IAA Press Conference (Photo: Business Wire)
The BYD HAN (E-segment sedan) and the BYD ATTO 3 (C-segment SUV) showcased at the Paris Motor Show last year are joined in Munich by some exciting new additions in the form of the versatile BYD DOLPHIN (C-segment hatchback) together with the dynamic D-segment sedan, BYD SEAL. Visitors to IAA can also enjoy a preview of the spacious, comfortable and practical BYD SEAL U (D-segment SUV) ahead of its forthcoming release in Europe.
For those with a penchant for ‘premium’, Munich also plays host to the first ever public presentation on European soil of the premium sub-brand, DENZA. The premium DENZA D9 MPV is a 7-seat vehicle (2+2+3 space) with a multitude of comfort, safety and performance innovations.
The European Launch of the sleek and sporty BYD SEAL D-sedan
Using BYD’s Ocean X Design Language, the dynamic BYD SEAL, built on the advanced e-Platform 3.0, epitomizes many of BYD’s latest technologies for safety, comfort and performance.
It is the first vehicle to utilise BYD’s innovative CTB (Cell-to-Body) technology which integrates the body and the Blade Battery for superior levels of structural strength, offering torsional stiffness at sports car level. The BYD SEAL all-wheel-drive also benefits from BYD's latest iTAC (Intelligent Torque Adaption Control) for advanced stability, handling and safety performance.
BYD SEAL is available in two trim levels: the rear-wheel-drive (RWD) 'Design' (230 kW) and the all-wheel-drive (AWD) ‘Excellence’ (390 kW), in six appealing colour options. The BYD SEAL offers a 570/520km (WLTP combined) driving range for practicality, with an exhilarating acceleration of 0-100 km in just 5.9/3.8 seconds depending on variant. The BYD SEAL utilises the 82.5 kWh ultra-safe, cobalt-free BYD Blade Battery.
Preview of the BYD SEAL U all-electric SUV
The D-segment SUV BYD SEAL U also makes its debut appearance in Munich. The spacious BYD SEAL U with capacity for five occupants and generous cargo space, is defined by its stylish Ocean inspired aesthetics, with high levels of safety, comfort and practicality. Representing excellent value in the all-electric SUV market, it will be available to European consumers during the first half of 2024.
Michael Shu, Managing Director, BYD Europe, says: “We are delighted to bring six of our latest NEV models to IAA, giving customers greater choices for eMobility. We have made significant progress in entering new markets in Europe. Just twelve months ago, we introduced our brand to Europe and in less than a year, we created a presence for our brand in 15 European countries and opened over 140 stores. We are working in conjunction with the very best dealer partners to create a network that delivers premium customer services and retail experiences. We look forward to expanding that further, giving more consumers the opportunity to experience the benefits and advanced technologies of BYD electric cars.”
Wolfgang Egger, BYD Design Director, added: “BYD’s design goal is to make a statement for the future, for new energy mobility to suit different needs. A key part of our design ethos is to preserve the motion and beauty of what we have enjoyed for so many years on ICE cars. And when we talk of the future, this goes beyond new platforms, new architecture choices, innovation in technology, and innovation in design. Our aim is to create an emotional connection, as we have done with the BYD SEAL and SEAL U through a combination of aesthetics, performance and technology.”
Committed to offering a diverse range of eco-friendly vehicles, BYD brings extensive choice, game changing innovation in EV technology and greater accessibility to electric mobility in Europe. Last year, globally BYD has achieved 1.86 million NEV car sales. BYD is also the first OEM to deliver 5 million NEVs globally, reaffirming its position as the world’s No.1 NEV brand as BYD also becomes a top 10 car brand worldwide.
Please check the high-resolution pictures: https://we.tl/t-Tcx91pqPsT
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
About BYD Europe
BYD Europe is headquartered in the Netherlands and is the first overseas branch of BYD Group, with a commitment to evolving the international brand BYD Auto to deliver safe and efficient sustainable solutions in new energy vehicles through world-leading technological innovations.
For more information, please visit www.byd.com.
To download our images, please visit https://www.byd.com/eu/image-bank
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905076263/en/
Contact information
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom